CARD9

caspase recruitment domain family member 9, the group of Caspase recruitment domain containing

Basic information

Region (hg38): 9:136363956-136373681

Links

ENSG00000187796NCBI:64170OMIM:607212HGNC:16391Uniprot:Q9H257AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • predisposition to invasive fungal disease due to CARD9 deficiency (Supportive), mode of inheritance: AR
  • predisposition to invasive fungal disease due to CARD9 deficiency (Strong), mode of inheritance: AR
  • deep dermatophytosis (Strong), mode of inheritance: AR
  • predisposition to invasive fungal disease due to CARD9 deficiency (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Immunodeficiency 103, susceptibility to fungal infectionsARAllergy/Immunology/InfectiousIndividuals can have recurrent (and lethal) fungal infections, and surveillance, prophylaxis, and early treatment may be beneficialAllergy/Immunology/Infectious19864672; 22703878; 23335372; 24131138

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CARD9 gene.

  • Predisposition to invasive fungal disease due to CARD9 deficiency (15 variants)
  • Inherited Immunodeficiency Diseases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CARD9 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
128
clinvar
6
clinvar
137
missense
210
clinvar
8
clinvar
1
clinvar
219
nonsense
8
clinvar
1
clinvar
9
start loss
0
frameshift
8
clinvar
1
clinvar
9
inframe indel
7
clinvar
7
splice donor/acceptor (+/-2bp)
3
clinvar
3
splice region
8
16
1
25
non coding
10
clinvar
64
clinvar
10
clinvar
84
Total 16 4 231 200 17

Highest pathogenic variant AF is 0.0000263

Variants in CARD9

This is a list of pathogenic ClinVar variants found in the CARD9 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
9-136364010-A-G Predisposition to invasive fungal disease due to CARD9 deficiency • not specified Benign (Jan 24, 2024)365828
9-136364056-G-C Predisposition to invasive fungal disease due to CARD9 deficiency Likely benign (Jan 13, 2018)914318
9-136364058-A-C Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jan 12, 2018)365829
9-136364163-C-T Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jan 12, 2018)365830
9-136364172-C-T Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jan 13, 2018)365831
9-136364245-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jan 13, 2018)914319
9-136364304-A-G Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Oct 31, 2018)632538
9-136364308-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Likely benign (Sep 01, 2023)1907523
9-136364315-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Aug 23, 2022)2182479
9-136364317-G-A Predisposition to invasive fungal disease due to CARD9 deficiency • CARD9-related disorder Benign (Jan 29, 2024)467796
9-136364320-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Likely benign (Dec 30, 2022)2894330
9-136364321-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Nov 22, 2022)1996192
9-136364321-GTGT-G Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Oct 25, 2022)841108
9-136364323-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Likely benign (Jul 30, 2022)2179651
9-136364335-C-T Predisposition to invasive fungal disease due to CARD9 deficiency Likely benign (Dec 17, 2018)799048
9-136364336-G-C Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jun 13, 2022)1461407
9-136364337-T-C Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Mar 17, 2021)1517165
9-136364339-G-A Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Jan 13, 2018)976604
9-136364342-T-G Predisposition to invasive fungal disease due to CARD9 deficiency • Inborn genetic diseases Uncertain significance (Nov 01, 2022)535814
9-136364346-C-G Predisposition to invasive fungal disease due to CARD9 deficiency • Inborn genetic diseases Uncertain significance (Sep 19, 2022)646780
9-136364348-C-T Predisposition to invasive fungal disease due to CARD9 deficiency • Inborn genetic diseases Conflicting classifications of pathogenicity (May 12, 2024)1036833
9-136364350-G-C Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Feb 14, 2021)1509981
9-136364350-GTCC-G Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Sep 01, 2021)1476736
9-136364351-T-G Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (Apr 23, 2021)1345984
9-136364352-C-G Predisposition to invasive fungal disease due to CARD9 deficiency Uncertain significance (May 07, 2022)2135129

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CARD9protein_codingprotein_codingENST00000371732 1211779
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
8.15e-130.24412467628561255340.00342
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.09973553600.9850.00002633444
Missense in Polyphen79108.540.72786975
Synonymous-1.561841591.160.00001131023
Loss of Function1.042227.90.7880.00000128312

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.002150.00214
Ashkenazi Jewish0.007220.00719
East Asian0.0004390.000435
Finnish0.0009260.000878
European (Non-Finnish)0.005540.00547
Middle Eastern0.0004390.000435
South Asian0.002100.00209
Other0.002470.00245

dbNSFP

Source: dbNSFP

Function
FUNCTION: Adapter protein that plays a key role in innate immune response to a number of intracellular pathogens, such as C.albicans and L.monocytogenes. Is at the crossroads of ITAM- tyrosine kinase and the Toll-like receptors (TLR) and NOD2 signaling pathways. Probably controls various innate immune response pathways depending on the intracellular pathogen. In response to L.monocytogenes infection, acts by connecting NOD2 recognition of peptidoglycan to downstream activation of MAP kinases (MAPK) without activating NF-kappa-B. Also involved in activation of myeloid cells via classical ITAM-associated receptors and TLR: required for TLR-mediated activation of MAPK, while it is not required for TLR-induced activation of NF-kappa-B (By similarity). Controls CLEC7A (dectin-1)-mediated myeloid cell activation induced by the yeast cell wall component zymosan, leading to cytokine production and innate anti-fungal immunity: acts by regulating BCL10-MALT1-mediated NF-kappa-B activation pathway. Activates NF-kappa-B via BCL10. In response to the hyphal form of C.albicans, mediates CLEC6A (dectin-2)-induced I-kappa-B kinase ubiquitination, leading to NF-kappa-B activation via interaction with BCL10. In response to fungal infection, may be required for the development and subsequent differentiation of interleukin 17-producing T helper (TH-17) cells. {ECO:0000250, ECO:0000269|PubMed:11053425}.;
Disease
DISEASE: Candidiasis, familial, 2 (CANDF2) [MIM:212050]: A primary immunodeficiency disorder with altered immune responses and impaired clearance of fungal infections, selective against Candida. It is characterized by persistent and/or recurrent infections of the skin, nails and mucous membranes caused by organisms of the genus Candida, mainly Candida albicans. {ECO:0000269|PubMed:19864672, ECO:0000269|PubMed:23335372, ECO:0000269|PubMed:24131138}. Note=The disease is caused by mutations affecting the gene represented in this entry. Defects induce reduced numbers of CD4(+) Th17 lymphocytes as well as a lack of monocyte-derived cytokines in response to Candida strains. Neutrophils show a selective Candida albicans killing defect with abnormal ultrastructural phagolysosomes and outgrowth of hyphae (PubMed:23335372). {ECO:0000269|PubMed:23335372}.;
Pathway
NOD-like receptor signaling pathway - Homo sapiens (human);C-type lectin receptor signaling pathway - Homo sapiens (human);Tuberculosis - Homo sapiens (human);Nucleotide-binding Oligomerization Domain (NOD) pathway;NOD1/2 Signaling Pathway;Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways;CLEC7A (Dectin-1) signaling;C-type lectin receptors (CLRs);Innate Immune System;Immune System (Consensus)

Recessive Scores

pRec
0.139

Intolerance Scores

loftool
0.827
rvis_EVS
-0.59
rvis_percentile_EVS
18.23

Haploinsufficiency Scores

pHI
0.0928
hipred
Y
hipred_score
0.533
ghis
0.537

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.814

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Card9
Phenotype
hematopoietic system phenotype; homeostasis/metabolism phenotype; immune system phenotype;

Gene ontology

Biological process
stimulatory C-type lectin receptor signaling pathway;I-kappaB kinase/NF-kappaB signaling;response to fungus;response to peptidoglycan;response to muramyl dipeptide;positive regulation of interleukin-6 production;positive regulation of tumor necrosis factor production;positive regulation of stress-activated MAPK cascade;regulation of tumor necrosis factor biosynthetic process;regulation of apoptotic process;positive regulation of I-kappaB kinase/NF-kappaB signaling;response to exogenous dsRNA;regulation of interleukin-2 biosynthetic process;innate immune response;regulation of interleukin-6 biosynthetic process;positive regulation of JNK cascade;defense response to Gram-positive bacterium;defense response to virus
Cellular component
cytoplasm;cytosol;plasma membrane
Molecular function
protein binding;protein homodimerization activity;CARD domain binding